Pralatrexate - Allos Therapeutics

Drug Profile

Pralatrexate - Allos Therapeutics

Alternative Names: 10-Propargyl-10-deazaaminopterin; Difolta; Folotyn; PDX

Latest Information Update: 23 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center; Southern Research Institute; SRI International
  • Developer Allos Therapeutics; Columbia University; Mundipharma International; Rafa Laboratories
  • Class Antineoplastics; Pterins; Small molecules
  • Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T cell lymphoma; Diffuse large B cell lymphoma; Hodgkin's disease; Peripheral T-cell lymphoma; Follicular lymphoma; Bladder cancer; Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase I/II Lymphoma; Multiple myeloma
  • No development reported B cell lymphoma; Bladder cancer; Breast cancer; Cutaneous T cell lymphoma; Hodgkin's disease; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 13 Dec 2017 Updated efficacy and adverse events data from a phase I trial in peripheral T-cell lymphoma (Combination therapy) presented at the 59th Annual Meeting of the American Society of Hematology (ASH-2017)
  • 09 Dec 2017 Updated efficacy and adverse events data from a phase I trial in Peripheral T-cell lymphoma presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
  • 23 Oct 2017 Mundipharma completes a phase I/II trial in Peripheral T-cell lymphoma (second-line therapy or greater) in Japan, before October 2017 (NCT02013362)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top